MEDTECH ACQUISIT(MTAC) - 2025 Q2 - Quarterly Results

TriSalus Life Sciences Second Quarter 2025 Results and Provides Updated 2025 Guidance Company delivers $11.2M in revenues resulting in 52% growth year-over-year and 22% growth quarter-over-quarter Broadened PEDD portfolio with launch of TriNav FLX designed to improve access in tortuous vessels Confirming revenue guidance of at least 50% growth due to continued commercial momentum Company to Host Conference Call and Webcast today at 4:30pm ET DENVER – August 12, 2025 - TriSalus Life Sciences, Inc. (Nasdaq: T ...